Cancer Immunotherapy Principles and Practice: Reflects Major Advances in Field of Immuno-Oncology and Cancer Immunology

Thoroughly updated to reflect major advances in the field of immuno-oncology, this second edition of __Cancer Immunotherapy Principles and Practice,__ from the Society for Immunotherapy of Cancer (SITC), remains the definitive resource for information on tumor immunology and cancer immunotherapy treatments. An essential reference for both novice and experienced cancer researchers, oncologists, and related practitioners alike, the book not only guides readers through the fundamental scientific principles of the field all the way to translational and practical clinical applications for treating and managing oncologic disease, but also provides a comprehensive understanding of the regulatory processes that support the safe and effective delivery of immunotherapy to patients with cancer. The expanded and updated second edition now spans 68 chapters, including 12 new chapters, covering major topics and innovations that have shaped the rapid development of immunotherapy and its ascension into the standard of care as first-line treatment for a growing number of disease settings. New to this edition are chapters with deeper insight into our understanding of cancer genomics and determinants of response, immunogenic cell death, cancer and stromal cell-intrinsic pathways of immune resistance, cancer immune exclusion, adoptive cell therapy, metabolomics, tumor mutation burden, immunotherapy in combination with radiation therapy, synthetic biology, and more. Complete with detailed illustrations, tables, and key points for targeted reference, __Cancer Immunotherapy Principles and Practice, Second Edition__ is the most comprehensive and authoritative resource for scientists and clinicians looking to expand their knowledge base of this dynamic field. **Key Features:** * Offers key insights and perspectives on cancer immunology and immunotherapy treatments from renowned experts in the field * Covers the basic principles and science behind cancer immunotherapy and tumor immunology * Includes treatment strategies for a vast array of available immunotherapy classes and agents, such as cytokine therapies, oncolytic viruses, cancer vaccines, CAR T therapies, and combination immunotherapies * Provides essential information on FDA-approved immunotherapies, including clinical management and outcome data related to response rates, risks, and toxicities * Discusses special considerations for immunotherapy in the context of specific disease settings, including skin cancers, genitourinary cancers, gastrointestinal cancers, hepatocellular carcinomas, gynecologic malignancies, breast cancers, lung cancers, head and neck cancers, brain tumors, sarcomas, pediatric cancers, and treatments combined with radiation therapy * Clarifies the complex regulatory aspects behind the development and approval of immunotherapy drugs * Purchase includes access to the eBook for use on most mobile devices or computers * Publisher: Springer Publishing Company Cancer Immunotherapy Principles and Practice Reflects Major Advances in Field of Immuno-Oncology and Cancer Immunology (Lisa H. Butterfield, Howard L. Kaufman etc.) (z-lib.org) Cover Title Copyright Contents Contributors Preface About the Society for Immunotherapy of Cancer Acknowledgments Abbreviation List Chapter 1: History of Cancer Immunotherapy Introduction Early Days of Immunotherapy Monoclonal Antibodies Cytokines and Nonspecific Immune Activators Vaccines Overcoming Immunosuppressive Factors Conclusion Key References Section I: Basic Principles of Tumor Immunology Chapter 2: Introduction to Basic Sciences: The Caduceus of Cancer-Immune Responsiveness and Cancer Biology Modern Immunotherapy of Cancer Most Malignant Tumors in Adults are Epithelial Damage-Associated Molecular Pattern Molecules Including HMGB1 Promote the Tumor Microenvironment and local andSystemic autophagy Innate Immunity Initiates the Immune Response Against Cancer T Cells are Central to the Immune Response to Cancer Acquired Resistance to T Cells Involves Tumor Intrinsic and Emergent Changes in the Tumor Microenvironment Immunotherapy Against Cancer Exploits a Natural and Broadly Conserved Immunological Behavior Tumor Rejection is the Extreme Manifestation of a Continuum of Immune Surveillance Tumor Rejection is Multifactorial; in Particular, Cancer Rejection is Characterized by Genetic Instability of the Target Tissue, Adding Complexity to the Understanding of its Mechanisms Initiating an Immune Response: The Outstanding Question Integrating Cancer Biology and Tumor Immunology Back to Cancer Biology Complex Problems do not Necessarily Demand Complex Solutions Conclusion Key References Chapter 3: Genomic Determinants of Cancer Immune Response and Resistance Introduction Tumor Immune “Visibility” Tumor Immune “Susceptibility” Conclusion Key References Chapter 4: Human Tumor Antigens Recognized by T Lymphocytes Introduction Tumor Antigen Discovery Process Classes of Human Tumor Antigens Recognized by T Cells Other Types of Tumor Antigens Tumor Antigens Recognized by Antibodies or Chimeric Antigen Receptors Conclusion Key References Chapter 5: Structural and Functional Defects in HLA Class I Antigen Processing Machinery in Cancer Cells: Molecular Mechanisms and Clinical Relevance Introduction HLA Class I APM Structure and Function Methodology to Detect HLA Class I APM Component Expression in Tumor Tissues HLA Class I APM Component Defects in Cancer Molecular Mechanisms Underlying Defects in HLA Class I APM Components In Malignant Cancers Clinical Significance of HLA Class I APM Component Defects in Cancer Cells Potential Role of HLA Class I APM Component Defects in Resistance to Treatment with Checkpoint Inhibitor-Based Immunotherapy Conclusion Key References Chapter 6: Systems Biology of T Cells Introduction Resources and Tools Used to Generate Data for Systems Biology Approaches Application of Systems Biology Approaches in Cancer Biology Application of Simulation-Based Analysis Conclusion Key References Chapter 7: Activation of CD4+ T Lymphocytes Introduction The in Vivo Anatomy of T Cell Activation Sequence of T Cell Activation Signals for T Cell Activation Effector and Memory CD4+ T Cells Conclusion Acknowledgments Key References Chapter 8: Regulation of Cell-Mediated Immunity: The Biology of Checkpoints and Regulatory T Cells Introduction Immunological Tolerance: Basic Principles Immune Checkpoints Maintained by Inhibitory Receptors Regulatory T Cells Conclusion Acknowledgments Key References Chapter 9: B Cells in Solid Tumors: Their Role in Tumor Pathogenesis and Antitumor Immunity Introduction B Cell Suppression of Antitumor Immunity: Early Evidence Mechanisms of B Cell Suppression of Antitumor Immunity B Cell Effects on Tumor Angiogenesis B Cell Effects on Metastases B Cells in Prostate, Pancreatic, Gastrointestinal, and Hepatocellular Cancers and Other Solid Tumors Summary B Cells may Mediate Antitumor Effects: The Role of Tertiary Lymphoid Structures Conclusion Key References Chapter 10: Functional Status of T Cells: Stemness Versus Terminal Differentiation Introduction Semantics Characteristics of T Cell Exhaustion (TEX) Characteristics of T Memory Stem Cells (Tscm) Cellular Metabolism and Hypoxia Clinical Implications Conclusion Key References Chapter 11: The Innate Immune System: Macrophages and Neutrophils Introduction Myeloid Cells in Cancer High-Dimensional Single-Cell Profiling of Tumor-Infiltrating Myeloid Cells Myeloid Cells in Tumor Initiation and Progression Prognostic Significance of Myeloid Cells in Cancer Suppression of Adaptive Immunity by Myeloid Cells Myeloid Cells and Immunotherapies Conclusion Key References Chapter 12: Natural Killer Cell Effector Mechanisms Against Solid Tumors and Leukemias and Their Exploitation in Immunotherapy Natural Killer Cell Effector Mechanisms and Their Distribution Among Distinct Natural Killer Cell Subsets and Body Compartments Exploitation of Natural Killer Cell Effector Mechanisms Against Hematologic Malignancies Exploitation of Natural Killer Cell Effector Mechanisms Against Solid Tumors Conclusion Key References Chapter 13: Immunogenic Cell Death and Cancer Introduction Antigenicity Adjuvanticity Microenvironment Implications for Cancer Therapy Conclusion Acknowledgments Key References Chapter 14: Cancer Cell-Intrinsic Pathways of Immune Resistance Introduction Immunological Effects and Therapeutic Targeting of Selected Oncogenic Driver Mutations EGFR Pathway Activation and Responsiveness to Immunotherapy in Non-Small Cell Lung Cancer Impact of Upregulated PI3K/AKT/MTOR Pathway in Cancer Resistance to Immunotherapy The WNT/Β-Catenin Pathway and Immune Response Conclusion Key References Chapter 15: Chemokines and Chemokine Receptors: Regulators of Tumor Immunity Introduction Chemokines Network in Antitumor Immune Response Chemokine Network in Protumor Immune Response Emerging Immunotherapies Targeting Chemokine Receptors and Chemokines Conclusion Key References Chapter 16: Role of the Tumor Microenvironment Tumors Depend on Suppressive Mechanisms in the Tumor Microenvironment for Survival CTLA-4 and PD-1 Pathways: The Classic Immune Checkpoints Defective Antigen-Presenting Cells in the Tumor Milieu TGF-β and the “Cold” Tumor Microenvironment Indoleamine 2,3-Dioxygenase and Tolerance to Tumor Cells Overcoming Therapy-Induced Counter-Regulation Activated Regulatory T Cells Induced by Tumors The Tumor Microenvironment as a Target for Therapy Conclusion Acknowledgments Key References Chapter 17: Cancer-Immune Exclusion: An Enigmatic Phenomenon The Enigma of Immune Exclusion Clinical Relevance of Immune Exclusion Immune Infiltration as the Hallmark of Immune Surveillance Prevalence of Immune Exclusion in Human Cancers Mechanisms of Immune Exclusion Conclusion Key References Chapter 18: Cancer Biomarkers: Tumor-Infiltrating T Cells Programmed Death-Ligand 1, and Tumor Mutation Burden Introduction Immune Biomarkers for Immune Checkpoint Blockade Tumor Mutation Burden in Cancer Immunotherapy Conclusion Key References Chapter 19: Role of the Microbiota in Carcinogenesis and Cancer Therapy Introduction Immune System Toning by the Microbiota Conclusion Key References Chapter 20: Synthetic Biology for the Immunotherapy of Cancer Introduction to the Field Synthetic Immunology Sensing Inputs Processing and Control Actuation and Output Future Perspective Conclusion Key References Section II: Cancer Immunotherapy Targets and Classes Chapter 21: Introduction to Principles of Cancer Immunotherapy Premise for Cancer Immunotherapy Key Components of the Antitumor Immune Response: General Considerations Tumor Recognition and the Integration of Innate and Adaptive Immunity Adaptive Immunity and the T Cell-Mediated Immune Response The Tumor Fights Back: Evasion and Subversion of the Host Immune Response Therapeutic Strategies for Cancer Immunotherapy Enhancing Immune Surveillance Mobilizing and Focusing the Antitumor Immune Response Activating and Driving the Antitumor Immune Response Taking the Brakes off the Immune Response Reversal of Tumor-Mediated Immune Suppression Conclusion Key References Chapter 22: Manipulating Innate Immune Pathways for Cancer Immunotherapy Introduction Innate Immune Pathways Mediating Host Antigen-Presenting Cell Activation in the Tumor Context Innate Lymphoid Cell Populations Influence of the Host Microbiota Therapeutic Interventions Based on the Manipulation of Innate Immunity Conclusion Key References Chapter 23: Cancer Vaccines: Considerations of Antigen, Formulation, and Delivery Introduction Tumor Neoantigen-Based Cancer Vaccines Promoting Memory T Cell Development During Therapeutic Cancer Vaccination Nanoparticle Vaccines as Novel Delivery Vehicles to Promote Antigen Uptake by Pro-Inflammatory Dendritic cell Populations Conclusion Key References Chapter 24: T Cell Modulatory Cytokines Introduction Cytokine Overview Type 1 and Type 2 Cytokines and Cell-Mediated Cytotoxicity Conclusion Key References Chapter 25: Non-Engineered Adoptive T Cell Therapy Introduction The Beginnings of Adoptive T Cell Therapy Adoptive Transfer of Tumor-Infiltrating Lymphocytes Endogenous T Cell Therapy Adoptive T Cell Therapy for Solid Tumors Beyond Melanoma Adoptive T Cell Therapy in Combination Strategies Desirable T Cell Phenotypes for Adoptive T Cell Therapy Adoptive Transfer of GD T Cells Conclusion Key References Chapter 26: CAR T Cell Therapy Introduction Genetic modification of T Cells With T cell Receptors Genetic Modification of T cells With Synthetic Receptors Barriers to Effective Adoptive T Cell Transfer and Potential Solutions Cell Manufacturing and Allogeneic Approaches Conclusion Key References Chapter 27: Immunotherapy Based on Blocking T Cell Inhibitory Pathways Introduction Basic Biology of Negative Regulatory Pathways Metabolic Negative Regulators of T Cells Therapeutic Targeting of Immune Checkpoints Immune-Related Toxicities Associated With Immune Checkpoint Inhibitors Conclusion Key References Chapter 28: Agonistic Antibodies to Co-Stimulatory Molecules Introduction Co-Stimulatory Molecules and Their Effects in Cancer Development Conclusion Key References Chapter 29: Immune Effects of Conventional Cancer Therapeutics Introduction On-Target Immune Effects Off-Target Immune Effects Potential Role of the Genetic Background of the Host Conclusion Key References Chapter 30: Oncolytic Viruses History of Oncolytic Viruses Virus Biology and the Principles of Oncolytic Virotherapy Methods for Improving OV Safety and Efficacy Families of Oncolytic Viruses in Clinical Development The Clinical Development of Talimogene Laherparepvec (T-VEC) Oncolytic Viruses Exert Their Antitumor Effects Through Multiple Mechanisms of Action Barriers to Oncolytic Viruses Delivery and Alternative Strategies to Overcome Them Alternative Strategies to Enhance Oncolytic Virus Efficacy Safety Concerns With Oncolytic Virus Clinical Development Conclusion Key References Chapter 31: Metabolism of Tumor Immunity Introduction The Metabolism of Highly Proliferative Cells Metabolism, the Tumor Microenvironment, and Immunity Therapeutic Implications of Cancer Immunometabolism Conclusion Key References Chapter 32: Principles of Combination Immunotherapies Introduction Building Combination Therapies on the Backbone of the Programmed Cell Death 1 Pathway Inhibition “Immuno Plus Immuno” Combination Therapies “Immuno Plus Standard of Care” Combination Therapies Targeting the Microenvironment Strategies to Minimize Combination-Associated Toxicity: Dosing, Sequencing, and Lessons From Initial Experience Biomarkers for Combination Immunotherapies Conclusion Key References Section III: Immune Function in Cancer Patients Chapter 33: Introduction to Immune Function in Cancer Patients Chapter 34: Tumor-Infiltrating Myeloid Cells in Cancer Progression and Therapy Response Introduction Monocytes and Immature Myeloid Cells Macrophages (MΦ) Dendritic Cells Granulocytes Neutrophils Mast Cells Eosinophils Basophils Methods for Profiling Myelomonocytic Cells in Cancer Myeloid Cells and Response to Cancer Chemotherapy Myeloid Cells as Targets for Cancer Immunotherapy Conclusion Key References Chapter 35: Intratumoral Gene Signatures and Host Genetic Variations Associated With Immune Responsiveness Introduction Part 1: Intratumoral Signatures Associated With Immune Responsiveness Part 2: Host Genetic Variations Associated With Immune Responsiveness Conclusion Key References Chapter 36: Impact of Somatic Mutations on the Local and Systemic Antitumor Immune Response Introduction Impact of Somatic Mutations on Gene Expression and Protein Function Establishing a Local and Productive Antitumor Immune Response Conclusion Acknowledgments Key References Chapter 37: Tumor Antigen Profiling Introduction Biology of Neoantigens Evidence for Clinical Relevance of Neoantigens Neoantigen Discovery Translation Application for Neoantigens Conclusion Key References Chapter 38: Assessment of Antitumor Immunity in Blood and Lymph Nodes Assessment Of Antitumor Immunity in Blood and Lymph Nodes Importance of T Cell Avidity Conclusion Key References Chapter 39: Regulatory T Cell Biology and Its Applications in Cancer Immunotherapy Introduction Treg Cell Identity Heterogeneity and Plasticity Among FOXP3+ Treg Cell Subsets Metabolic Regulation of Treg Cell Phenotype Targeting Treg Cells in Cancer Patients Conclusion Acknowledgments Key References Chapter 40: Systemic Measures of Immune Function in Cancer Patients: Other Suppressive Cellular Mechanisms Introduction Regulatory T Cells Myeloid-Derived Suppressor Cells Tumor-Associated Macrophages Other Immunosuppressive Cell Types Therapies for Targeting Immmunosuppressive Populations Conclusion Key References Chapter 41: Circulating Mediators of Tumor-Induced Immune Suppression Introduction Regulatory T Cells in Cancer Myeloid-Derived Suppressor Cells in Cancer Tumor-Derived Exosomes Interactions of Tumor-Derived Exomes and Immune Cells Tumor-Derived Exome and Regulatory T Cell Collaboration Effects of Tumor-Derived Exomes on Functions of Cd8+ Effector Cells and Natural Killer Cells Evaluation of Reprogrammed Non-Tumor-Derived Exomes in Cancer Patients’ Plasma Mechanisms Involved in Small Extracellular Vesicle-Mediated Immune Suppression in Cancer Biological Significance of Tumor-Derived Exomes in Cancer Conclusion Key References Chapter 42: Harnessing B Cells and Tertiary Lymphoid Structures for Antitumor Immunity Introduction Brief Primer on B Cell Differentiation and Maturation Clinical Significance Of B Cells and Tertiary Lymphoid Structures in Human Tumors Heterogeneity of B Cells and Tertiary Lymphoid Structures in the Tumor Microenvironment How do Intratumoral B Cells Contribute to Tumor Immunity? Harnessing B Cells and Tertiary Lymphoid Structures for Cancer Immunotherapy Conclusion Key References Chapter 43: Blood Transcriptomic Approaches to Cancer Immunotherapy Background: Immunomonitoring and Cancer Immunotherapy Blood Transcriptomics Technology Primer The Use of Blood Transcriptomics Blood Transcriptome Module Repertoires Conclusion Key References Chapter 44: Advances in Techniques for Immunotherapy Biomarker Analysis Introduction Tumor-Based Biomarkers Minimally Invasive Biomarkers Stool-Based Biomarker Assays Metabolomics Conclusion Key References Chapter 45: Predictive Biomarkers (Programmed Death Ligand 1 Expression, Microsatellite Instability, and Tumor Mutational Burden) for Response to Immune Checkpoint Inhibitors Introduction Programmed Death Ligand 1 Expression Analysis Microsatellite Instability Tumor Mutational Burden Conclusion Acknowledgments Key References Chapter 46: Tumor Microenvironment Metabolism as a Primordial Checkpoint in Antitumor T Cell Immunity Introduction Deregulated Metabolism as a Key Hallmark of Tumor Cells Metabolic Features of the Tumor Microenvironment T Cell Activation and Metabolism Metabolic Regulation of T Cell Effector Function and Fate Nutrient Sensing in Control of T Cell Fate and Function T Cell Hyporesponsive Phenotypes and Their Metabolic Links Implications for Effective Antitumor Immunity and Improvements in Immunotherapy Conclusion Key References Chapter 47: Age-Related Immune Function Changes as They Relate to Cancer Immunotherapy Introduction Immunosenescence Peripheral Immune Parameters Correlating With Cancer Patient Survival Expected Effect Of Age on the Response To Shared Antigens Versus Neoantigens, and Remedial Action Conclusion Key References Chapter 48: Clinical Measures: Tumor Response Assessments, Pseudoprogression, and Immunometabolism Introduction Imaging-Based Response Criteria Imaging Modalities and Novel Techniques Defining and Managing Pseudoprogression Immunometabolism Tissue-Based Immunometabolism Response Monitoring Conclusion Key References Section IV: Disease-Specific Treatments and Outcomes Chapter 49: Introduction: General Approach to Cancer Immunotherapy-Lessons Learned From the Past Years Introduction Checkpoint Inhibitors Differential Effect on the Basis of Biology Biomarkers Unique Safety Profile From Metastatic Disease to Adjuvant Therapy Neoadjuvant Therapy: The Next Step Efficacy in Brain Metastases Conclusion Key References Chapter 50: Immunotherapy in Melanoma Introduction Melanoma and Immune System Cytokines Conclusion Key References Chapter 51: Other Cutaneous Tumors: Basal Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Cutaneous Sarcomas Introduction Basal Cell Carcinoma Cutaneous Squamous Cell Carcinoma Merkel Cell Carcinoma Cutaneous Sarcomas Conclusion Key References Chapter 52: Immunotherapy in Genitourinary Malignancies Introduction Renal Cell Carcinoma Bladder Cancer Prostate Cancer Conclusion Key References Chapter 53: Immunotherapy in Gastrointestinal Malignancies Introduction Immune-Modulatory Targets in Gastric Cancer Molecular Subtypes Early Clinical Data With Checkpoint Inhibitors in Gastric Cancer Other Immune-Modulatory Approaches in Gastric Cancer Role of Programmed Cell Death 1/Programmed Death Ligand 1 Inhibition in Gastric Cancer Role of Immune Modulation in Colorectal Cancer Scientific Rationale and Clinical Data for Immunotherapy in Microsatellite Instability High Colorectal Cancer Impact of Immunotherapy on Microsatellite Instability High Colorectal Cancer Rationale for Immune Checkpoint Therapy in Esophageal and Esophagogastric Junction Cancers Clinical Data for Immune Checkpoint Therapy in Esophageal and Esophagogastric Junction Cancers Conclusion Key References Chapter 54: Immunotherapy of Hepatocellular Carcinoma Background, Epidemiology, and Risk Factors Hepatocellular Carcinoma Treatments The Immunological Environment in Hepatocellular Carcinoma Hepatic Immune Tolerogenesis Pathogenesis and Progression of Hepatocellular Carcinoma: Immune-Mediated Mechanisms Immunotherapeutic Approaches Vaccines Adoptive Transfer of Genetically Modified Lymphocytes Treatment of Hepatocellular Carcinoma Based on Natural Killer Cells Toll-Like Receptor Agonists Predictive Biomarkers Programmed Death Ligand 1 Expression Tumor Mutational Burden The Gut Microbiota as Potential Biomarker Systemic Therapy in Advanced Hepatocellular Carcinoma Anti-Programmed Cell Death Protein 1 Antibodies Anti-Programmed Death Ligand 1 Antibodies Anti-Cytotoxic T Lymphocyte-Associated Protein 4 Antibodies Combination Therapies Between Immune Checkpoint Inhibitors and Other Drugs Immunotherapy in Localized Disease Conclusion Key References Chapter 55: Immunotherapy for Gynecologic Malignancies Introduction Ovarian Cancer Endometrial (Uterine) Cancer Cervical Cancer Conclusion Key References Chapter 56: Breast Cancer Immunotherapy Introduction Breast Cancer is a Heterogeneous Disease Molecular Targets for Breast Cancer Therapy Host–Tumor Interactions and Breast Cancer Immunotherapy Immune Checkpoint Modulation for Metastatic Breast Cancer Immune Checkpoint Modulation for Early Breast Cancer Breast Cancer Vaccines for Therapy and Prevention Conclusion Key References Chapter 57: Immunotherapy for Lung Cancer and Malignant Pleural Mesothelioma Introduction Lung Cancer Vaccine Immune Checkpoint Inhibitors Treatment Evaluation of Tissue Biopsy at the Time of Diagnosis Mesothelioma Immune-Related Toxicities Conclusion Key References Chapter 58: Head and Neck Cancer Introduction Immune Escape in Head and Neck Cancer Immunotherapeutic Strategies in Head and Neck Cancer Conclusion Key References Chapter 59: Immunotherapy of Hematologic Malignancies: Lymphomas, Leukemias, and Myeloma Immunotherapy of Hematologic Malignancies: Unique Opportunities and Challenges Lymphomas and Lymphoid Leukemias Multiple Myeloma Acute Myeloid Leukemia Conclusion Key References Chapter 60: Brain Tumors Primary and Secondary (Metastatic) Brain Tumors Immunology of the Brain and Brain Tumors Immunotherapeutic Approaches for Brain Tumors—Recent Clinical Trials Oncolytic Viroimmunotherapy for Glioma Perspectives of Immunotherapy in Brain Cancers Conclusion Key References Chapter 61: Sarcomas Introduction To Sarcomas The Sarcoma Tumor Immune Microenvironment Immune Checkpoint Inhibitors Adoptive Cellular Therapy Vaccination Strategies Other Immunotherapy Strategies Conclusion Key References Chapter 62: Pediatric Cancers: Neuroblastoma Introduction Pediatric Cancers: Neuroblastoma Neuroblastoma Passive Immunotherapy Active Immunotherapy Future Directions Conclusion Key References Chapter 63: Immunotherapy in Combination With Radiation Therapy Introduction The Immune System Contributes to the Success of Radiation Therapy Radiation Signals Danger and Activates Proinflammatory Pathways Immune-Adjuvant Effects of Radiation Therapy Abscopal Effect Immunosuppressive Effects of Radiation Therapy Radiotherapy–Immunotherapy Combinations Optimizing Radiotherapy-Immunotherapy Combinations Conclusion Key References Section V: Regulatory Aspects of the Biological Therapy of Cancer Chapter 64: Regulatory Considerations for Therapeutic Cancer Vaccines Introduction Chemistry, Manufacturing, and Control Considerations for Cancer Vaccines General Chemistry, Manufacturing, and Control Considerations for Viral Vectored Cancer Vaccines Specific Chemistry, Manufacturing, and Control Considerations for Viral Vectored Cancer Vaccines Specific Chemistry, Manufacturing, and Control Considerations for Neoantigen-Based Peptide Cancer Vaccines Specific Chemistry, Manufacturing, and Control Considerations for Dendritic Cell Cancer Vaccines Clinical Considerations for Cancer Vaccines Expedited Programs for Serious Conditions Conclusion Acknowledgments Key References Chapter 65: A Regulatory Perspective on Cell Therapy for Cancer: Chemistry, Manufacturing and Control, Preclinical, and Clinical Considerations Introduction Regulatory Chemistry, Manufacturing, and Control Considerations for Cell Therapy Products Chemistry, Manufacturing, and Control, Preclinical, and Clinical Regulatory Considerations for Different Classes of Immunotherapies Conclusion Acknowledgments Key References Chapter 66: Gene Therapy-Based Immunotherapy Products for Human Clinical Trials: Chemistry, Manufacturing and Control, Preclinical, and Clinical Considerations: An FDA Perspective Introduction Chemistry, Manufacturing, and Control Recommendations for Gene Therapy Products Preclinical Recommendations for Gene Therapy Products Clinical Considerations for Investigational Gene Therapy Products Considerations for Late-Stage Product Development Additional Considerations That are Applicable to Specific Product Classes Used in Immunotherapy Applications Conclusion Acknowledgments Key References Chapter 67: Combination Immunotherapies: Regulatory Considerations Introduction Combination Therapy is not Synonymous With Combination Product Combination Immunotherapy for Cancer Potential of the Combination of Cancer Immunotherapy Preclinical Considerations for Combination Therapies Clinical Considerations Combination Therapy: Safety Considerations Long-Term Follow-Up Companion Diagnostics Conclusion Key References Chapter 68: Regulatory Considerations for In Vitro Companion Diagnostic Devices Introduction In Vitro Companion Diagnostic Devices in Precision Medicine Food and Drug Administration Oversight of in Vitro Diagnostic Devices Resources Index David Icke - Perceptions of a Renegade Mind-David Icke Books (2021) copy 2 Copyright Title Page Dedication Contents Chapter 1: ‘I’m thinking’ – Oh, but are you? Chapter 2: Renegade perception Chapter 3: The Pushbacker sting Chapter 4: ‘Covid’: The calculated catastrophe Chapter 5: There is no ‘virus’ Chapter 6: Sequence of deceit Chapter 7: War on your mind Chapter 8: ‘Reframing’ insanity Chapter 9: We must have it? So what is it? Chapter 10: Human 2.0 Chapter 11: Who controls the Cult? Chapter 12: Escaping Wetiko Postscript Appendix: Cowan-Kaufman-Morell Statement on Virus Isolation Bibliography Index David Icke - Perceptions of a Renegade Mind-David Icke Books (2021) copy 3 Copyright Title Page Dedication Contents Chapter 1: ‘I’m thinking’ – Oh, but are you? Chapter 2: Renegade perception Chapter 3: The Pushbacker sting Chapter 4: ‘Covid’: The calculated catastrophe Chapter 5: There is no ‘virus’ Chapter 6: Sequence of deceit Chapter 7: War on your mind Chapter 8: ‘Reframing’ insanity Chapter 9: We must have it? So what is it? Chapter 10: Human 2.0 Chapter 11: Who controls the Cult? Chapter 12: Escaping Wetiko Postscript Appendix: Cowan-Kaufman-Morell Statement on Virus Isolation Bibliography Index David Icke - Perceptions of a Renegade Mind-David Icke Books (2021)_compressed copy 2 Copyright Title Page Dedication Contents Chapter 1: ‘I’m thinking’ – Oh, but are you? Chapter 2: Renegade perception Chapter 3: The Pushbacker sting Chapter 4: ‘Covid’: The calculated catastrophe Chapter 5: There is no ‘virus’ Chapter 6: Sequence of deceit Chapter 7: War on your mind Chapter 8: ‘Reframing’ insanity Chapter 9: We must have it? So what is it? Chapter 10: Human 2.0 Chapter 11: Who controls the Cult? Chapter 12: Escaping Wetiko Postscript Appendix: Cowan-Kaufman-Morell Statement on Virus Isolation Bibliography Index David Icke - Perceptions of a Renegade Mind-David Icke Books (2021)_compressed copy 3 Copyright Title Page Dedication Contents Chapter 1: ‘I’m thinking’ – Oh, but are you? Chapter 2: Renegade perception Chapter 3: The Pushbacker sting Chapter 4: ‘Covid’: The calculated catastrophe Chapter 5: There is no ‘virus’ Chapter 6: Sequence of deceit Chapter 7: War on your mind Chapter 8: ‘Reframing’ insanity Chapter 9: We must have it? So what is it? Chapter 10: Human 2.0 Chapter 11: Who controls the Cult? Chapter 12: Escaping Wetiko Postscript Appendix: Cowan-Kaufman-Morell Statement on Virus Isolation Bibliography Index

Thoroughly updated to reflect major advances in the field of immuno-oncology, this second edition of Cancer Immunotherapy Principles and Practice, from the Society for Immunotherapy of Cancer (SITC), remains the definitive resource for information on tumor immunology and cancer immunotherapy treatments. An essential reference for both novice and experienced cancer researchers, oncologists, and related practitioners alike, the book not only guides readers through the fundamental scientific principles of the field all the way to translational and practical clinical applications for treating and managing oncologic disease, but also provides a comprehensive understanding of the regulatory processes that support the safe and effective delivery of immunotherapy to patients with cancer.

The expanded and updated second edition now spans 68 chapters, including 12 new chapters, covering major topics and innovations that have shaped the rapid development of immunotherapy and its ascension into the standard of care as first-line treatment for a growing number of disease settings. New to this edition are chapters with deeper insight into our understanding of cancer genomics and determinants of response, immunogenic cell death, cancer and stromal cell-intrinsic pathways of immune resistance, cancer immune exclusion, adoptive cell therapy, metabolomics, tumor mutation burden, immunotherapy in combination with radiation therapy, synthetic biology, and more. Complete with detailed illustrations, tables, and key points for targeted reference, Cancer Immunotherapy Principles and Practice, Second Edition is the most comprehensive and authoritative resource for scientists and clinicians looking to expand their knowledge base of this dynamic field.

Key Features:

• Offers key insights and perspectives on cancer immunology and immunotherapy treatments from renowned experts in the field
• Covers the basic principles and science behind cancer immunotherapy and tumor immunology
• Includes treatment strategies for a vast array of available immunotherapy classes and agents, such as cytokine therapies, oncolytic viruses, cancer vaccines, CAR T therapies, and combination immunotherapies
• Provides essential information on FDA-approved immunotherapies, including clinical management and outcome data related to response rates, risks, and toxicities
• Discusses special considerations for immunotherapy in the context of specific disease settings, including skin cancers, genitourinary cancers, gastrointestinal cancers, hepatocellular carcinomas, gynecologic malignancies, breast cancers, lung cancers, head and neck cancers, brain tumors, sarcomas, pediatric cancers, and treatments combined with radiation therapy
• Clarifies the complex regulatory aspects behind the development and approval of immunotherapy drugs

"The second edition of Cancer Immunotherapy Principles and Practice, from the Society of Immunotherapy of Cancer, has been thoroughly updated to reflect major advances in the field of immuno-oncology in recent years and remains the definitive resource for information on tumor immunology and cancer immunotherapy treatments. An essential reference for both novice and experienced cancer researchers, oncologists, and related practitioners alike, the book not only guides readers through the fundamental scientific principles of the field all the way to translational and practical clinical applications for treating and managing oncologic disease, but also provides a comprehensive understanding of the regulatory processes that support the safe and effective delivery of immunotherapy to patients with cancer. The expanded and updated second edition covers major topics and innovations that have shaped the rapid development of immunotherapy and its ascension into the standard of care as first-line treatment for a growing number of disease settings. New to this edition are chapters with deeper insight into our understanding of cancer genomics and determinants of response, immunogenic cell death, cancer and stromal cell-intrinsic pathways of immune resistance, cancer immune exclusion, adoptive cell therapy, metabolomics, tumor mutation burden, immunotherapy in combination with radiation therapy, synthetic biology, and more. Complete with detailed illustrations, tables, and key points for targeted reference, Cancer Immunotherapy Principles and Practice, Second Edition is the most comprehensive and authoritative resource for scientists and clinicians looking to expand their knowledge base of this dynamic field"-- Provided by publisher